Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
SCRI Development Innovations, LLC
With
Amgen
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
All patients treated with at least one treatment of Vectibix(Panitumumab) from February 2004 -April 2009 are eligible for the study. Patients may or may not have had an infusion reaction to Vectibix (Panitumumab). Major infusion reactions are defined as rapid onset airway obstruction(bronchospasm, stridor, hoarseness), urticaria, erythema, and/or hypotension, anaphylaxis. Minor infusion reactions are defined as transient flushing or rash, urticaria, dyspnea, drug fever.
Patients who have received treatment with an EGFR in the past are eligible.
You may not be if
There will be no exclusions based on age, sex, medical history, or use of concomitant therapies. All charts will be abstracted for the same information, through completion of the last chemotherapy cycle.
Clareo Health | A Retrospective Cohort Study of Infusion Reactions Due to Vectibix
